| Recruiting | Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 Atopic Dermatitis (AD), Eczema | Phase 1 | 2026-03-02 |
| Recruiting | Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Psoriasis | Phase 1 | 2025-12-15 |
| Completed | Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis Atopic Dermatitis (Eczema) | Phase 2 | 2025-06-09 |
| Completed | Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) Scalp Psoriasis | Phase 3 | 2021-08-24 |
| Completed | Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STR Seborrheic Dermatitis | Phase 3 | 2021-07-08 |
| Completed | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED) Atopic Dermatitis Eczema | Phase 3 | 2021-04-07 |
| Terminated | Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo Vitiligo | Phase 2 | 2021-03-04 |
| Completed | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216) Psoriasis, Plaque Psoriasis | Phase 2 | 2021-03-01 |
| Completed | Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis Atopic Dermatitis Eczema | Phase 3 | 2021-02-25 |
| Completed | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II) Atopic Dermatitis Eczema | Phase 3 | 2021-02-24 |
| Completed | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis Atopic Dermatitis Eczema | Phase 3 | 2021-01-27 |
| Completed | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215) Psoriasis, Plaque Psoriasis | Phase 2 | 2020-11-30 |
| Completed | Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis Seborrheic Dermatitis | Phase 2 | 2020-06-12 |
| Completed | Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema Chronic Hand Eczema | Phase 1 / Phase 2 | 2020-04-20 |
| Completed | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis Plaque Psoriasis | Phase 1 | 2020-03-10 |
| Completed | Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis Chronic Plaque Psoriasis | Phase 3 | 2020-02-12 |
| Completed | Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis Plaque Psoriasis | Phase 2 | 2020-01-13 |
| Completed | Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Modera Atopic Dermatitis (Eczema) | Phase 1 | 2019-12-23 |
| Completed | Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis Chronic Plaque Psoriasis | Phase 3 | 2019-12-20 |
| Completed | Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis Chronic Plaque Psoriasis | Phase 3 | 2019-12-17 |
| Completed | Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis Seborrheic Dermatitis | Phase 2 | 2019-12-04 |
| Completed | Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis Atopic Dermatitis | Phase 2 | 2019-05-31 |
| Completed | Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis Plaque Psoriasis | Phase 2 | 2018-12-18 |
| Completed | The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis Plaque Psoriasis | Phase 2 | 2018-09-21 |
| Completed | Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasi Psoriasis | Phase 1 / Phase 2 | 2017-12-11 |